Medtronic product linked to surgery problems
Wall Street Journal (subscription required), September 4, 2008
A potent substance used in spine-repair surgery to promote bone growth has been linked to life-threatening complications in dozens of patients. Many of the complications involving the product, Medtronic Inc.'s "Infuse Bone Graft," have occurred during off label uses. Medtronic representatives said it is taking the reports seriously and has been active in warning doctors of certain problems related to use of the bone graft. They added, however, that the rate of complications is low and that reports to the FDA of problems represent one-tenth of 1% of the units sold.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Handshaking Spreads Germs. Get Over It.
- Healthcare Costs Start With What We Eat
- Hospitals Likely to Outsource ICD-10 at Launch
- IOM Identifies GME Problems, Calls for Finance Changes
- CMS Confirms ICD-10 Deadline
- Anatomy of 3 Health System Rebranding Efforts
- Premium Subsidy Fight Creating Uncertainty for Hospitals, Health Plans
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts